Conclusion: Tirzepatide demonstrates superior metabolic efficacy in direct comparative trials, whereas semaglutide currently has the strongest evidence for cardiovascular benefit
18 Collart J, Vandeponseele M, Bosschaert P
Its monthly dosing, coupled with up to 20% average weight loss at 52 weeks, positions it as one of the first contenders to rival bariatric surgery outcomes
HELPING YOU STAY ON TRACK Your ideal weight is within your grasp but you wont get there by starving yourself
another barrier-enhancing mechanism is where Akkermansia induces Paneth cells to produce antimicrobial peptides, and SCFAs from intestinal mucin glycoproteins are absorbed in the colon as an energy source for colonic cells, inducing regulatory T cells and exerting anti-inflammatory effects (Reunanen et al., 2015
d) CAR-T Cell Therapy: Chimeric Antigen Receptor (CAR) T-cell therapy involves genetically modifying a patient's T cells to express receptors that target cancer-specific antigens